PeptideDB

Kinetin

CAS: 525-79-1 F: C10H9N5O W: 215.21

Kinetin (N6-furfuryladenine) belongs to the family of N6-substituted adenine derivatives known as cytokinins, which are
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Kinetin (N6-furfuryladenine) belongs to the family of N6-substituted adenine derivatives known as cytokinins, which are plant hormones involved in cell division, differentiation and other physiological processes. Kinetin has anti-aging effects[1].
Invitro Kinetin (N6-furfuryladenine) shows to have a direct effect on superoxide dismutase activity in plants; prevent oxidation of unsaturated acids in plant membranes; slow down development and aging in insects, by reducing their fecundity and increasing the specific activity of catalase; and delay the onset of many age-related characteristics that appear in normal human skin fibroblasts undergoing aging in vitro. Kinetin (70-150 μM) markedly suppressed hydroxyl radical formation by about 41% and 76%, respectively[1]. The plant cytokinin kinetin dramatically increases exon 20 inclusion in RNA isolated from cultured familial dysautonomia (FD) cells[2].
In Vivo Kinetin (N6-furfuryladenine) (2-6 mg/kg; injection into the tail vein) effectively prevents ADP-induced acute pulmonary thrombosis in mice[1].Subjects received 23.5 mg/kg/d for 28 d. An increase in WT IKBKAP mRNA expression in leukocytes was noted after 8 d in six of eight individuals; after 28 d, the mean increase compared with baseline was significant[3]. Animal Model:
Name Kinetin
CAS 525-79-1
Formula C10H9N5O
Molar Mass 215.21
Appearance Solid
Transport Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Reference [1]. Hsiao G, et al. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur J Pharmacol. 2003 Apr 4;465(3):281-7. [2]. Hims MM, et al. Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med (Berl). 2007 Feb;85(2):149-61. [3]. Axelrod FB, et al. Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia. Pediatr Res. 2011 Nov;70(5):480-3. [4]. Griffaut B, et al. Cytotoxic effects of kinetin riboside on mouse, human and plant tumour cells. Int J Biol Macromol. 2004 Aug;34(4):271-5.